In Re Nektar Therapeutics: Ninth Circuit Affirms Dismissal Of Securities Class Action Arising From Failure Of Clinical Drug Trial - Securities

On May 19, 2022, a panel of the Ninth Circuit unanimously affirmed the district court's dismissal of a putative securities fraud class action accusing Nektar Therapeutics and several of...

Related Keywords

,Atossa Genetics Inc ,Nektar Therapeutics ,Bofi Holding ,Securities Exchange ,First Solar Inc ,Ninth Circuit ,Plainview Report ,Securities Exchange Act ,Materially False ,Misleading Statements ,Loss Causation ,Atossa Genetics ,Mineworker Pension Scheme ,Solar Inc ,Mondaq ,In Re Nektar Therapeutics Ninth Circuit Affirms Dismissal Of Securities Class Action Arising From Failure Clinical Drug Trial ,Corporate Commercial Law ,Corporate And Company Law ,Securities ,Food ,Drugs ,Healthcare ,Life Sciences ,Food And Drugs Law ,Litigation ,Ediation Amp Arbitration ,Class Actions ,